A+ A A-

Download article

A.Y. Krylov*, Y.V. Krylov**
Androgens and breast cancer (literature review)
*State Educational Establishment «Institute of Professional Development and Further Training of Staff of State Committee of Forensic Expert Examinations of the Republic of Belarus», Minsk, Republic of Belarus
**Public Health Establishment «Vitebsk Regional Clinical Pathoanatomical Bureau», Vitebsk, Republic of Belarus

In this review physiological properties of androgens, the characteristic of androgens receptors (AR), data on the level of androgens in biological fluids in breast cancer (BC) and the results of immunohistochemical (IHC) researches of AR expression in various biological subtypes of BC are presented. Up to this date there is no common opinion about the role of the level of androgens and their metabolites in biological fluids samples in the development of BC. At the same time, the availability of some publications about the difficulties in determining androgens, their precursors and metabolites in biological fluids testifies to the necessity to investigate the presence of АR in the cells of BC by means of molecular and biological methods, including IHC one. Recent publications about AR are devoted to their IHC revealing in BC, prognostic role in its development and prognosis. A hypothesis, that androgens are directly involved in BC cancerogenesis, is based on the presence of AR in the majority of breast carcinomas. Immunohistochemical data indicate, that a significant amount of poorly differentiated breast carcinomas are estrogen and progesterone negative, but АR positive. The researches concerning the prognostic value of AR positive expression are rather inconsistent, however, the opinion prevails, that female patients with tumours positive to АR, are characterised by the best, practically recurrence-free survival. In clinical view the elaborations of АR- targeted therapy are of the greatest interest. It emphasizes the necessity of further AR studying in various biological subtypes of BC and especially in triple negative breast cancer (ТNBC).
Key words: androgens, androgens receptors, breast cancer, immunohistochemical.


1. Semiglazov V, Semiglazov V, Paltuev R, Semiglazova T, Dashjan G. Biologicheskoe obosnovanie planirovanija lechenija raka molochnoj zhelezy [Biological justification of planning of a cancer therapy of a mammary gland]. Vrach. 2012;(11):2-4.
2. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008 Mar;14(5):1368-76.
3. Tyulyandin SA, Stenina MB, Frolova MA. Trojnoj negativnyj rak molochnoj zhelezy [Triad negative breast cancer]. Prakt. onkologija. 2010;11(4):247-52.
4. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple negаtive breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010 Dec;7(12):683-92.
5. Gao W. Androgen receptor as a therapeutic target. Adv Drug Deliv Rev. 2010 Oct;62(13):1277-84.
6. Shah PD, Gucalp A, Traina TA. The role of the androgen receptor in triple-negative breast cancer. Women's Health. 2013;9(4):351-60.
7. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009 Apr;15(7):2472-8.
8. Zhou J, Anderson K, Bievre M, Ng S, Bondy CA. Primate mammary gland insulin-like growth factor system: cellular localization and regulation by sex steroids. J Investig Med. 2001 Jan;49(1):47-55.
9. Avila DM, Zoppi S, McPhaul MJ. The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):135-42.
10. Forsbach G, Güitrón-Cantú A, Vázquez-Lara J, Mota-Morales M, Díaz-Mendoza ML. Virilizing adrenal adenoma and primary amenorrhea in a girl with adrenal hyperplasia. Arch Gynecol Obstet. 2000 Feb;263(3):134-6.
11. Karamanakos P, Mitsiades CS, Lembessis P, Kontos M, Trafalis D, Koutsilieris M. Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy. Anticancer Res. 2004 Mar-Apr;24(2C):1077-81.
12. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006 Jan;354(3):270-82.
13. Bulbrook RD, Thomas BS, Utsunomiya J, Hamaguchi E. The urinary excretion of 11-deoxy-17-oxosteroids and 17-hydroxycorticosteroids by normal Japanese and British women. J Endocrinol. 1967 Aug;38(4):401-6.
14. Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC, Hankinson SE. Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1032-6.
15. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006 Oct;98(19):1406-15.
16. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv. 2001 Jun;56(6):361-76.
17. Marinopoulos S, Dimitrakakis C, Tsigginou A, Ambela C, Antsaklis A. 0216 Testosterone protection: Salivary hormone levels in newly diagnosed breast cancer patients. The Breast. 2009 Mar;18(1):S72.
18. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med. 2006 Jul;166(14):1483-9.
19. Micheli A, Meneghini E, Secreto G, Berrino F, Venturelli E, Cavalleri A, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Veronesi U, Formelli F. Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol. 2007 Jul;25(19):2685-90.
20. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002 Apr;94(8):606-16.
21. Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):967-71.
22. Hofling M, Hirschberg AL, Skoog L, Tani E, Hägerström T, von Schoultz B. Testosterone inhibits estrogen/progestogen-ninduced breast cell proliferation in postmenopausal women. Menopause. 2007 Mar-Apr;14(2):183-90.
23. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause. 2004 Sep-Oct;11(5):531-5.
24. Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T, Sasano H. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab. 2001 May;86(5):2250-7.
25. Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW, Hunter DJ. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses’ Health Study. Cancer Res. 2002 Feb 15;62(4):1045-9.
26. MacLean HE, Brown RW, Beilin J, Warne GL, Zajac JD. Increased frequency of long androgen receptor CAG repeats in male breast cancers. Breast Cancer Res Treat. 2004 Dec;88(3):239-46.
27. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T, Nishiguchi Y. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008 Oct;13(5):431-5.
28. Cox DG, Blanché H, Pearce CL, Calle EE, Colditz GA, Pike MC, Albanes D, Allen NE, Amiano P, Berglund G, Boeing H, Buring J, Burtt N, Canzian F, Chanock S, Clavel-Chapelon F, Feigelson HS, Freedman M, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel L, Kraft P, LeMarchand L, Lund E, Palli D, Peeters PH, Riboli E, Stram DO, Thun M, Tjonneland A, Trichopoulos D, Yeager M. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res. 2006;8(5):R54.
29. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005 Jul;24(29):4660-71.
30. Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit. 2000 Mar-Apr;6(2):433-8.
31. Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002 Feb;80(2):175-89.
32. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993 May;170(1):31-5.
33. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA, Tamimi RM. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011 Apr;17(7):1867-74.
34. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 2003 Aug;98(4):703-11.
35. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010 Feb;23(2):205-12.
36. Gucalp A, Tolaney SM, Isakoff SJ, et al. Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). J Clin Oncol. 2012;20(18 suppl).  
37. Tsang JY, Ni YB, Chan SK, Shao MM, Law BK, Tan PH, Tse GM. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Ann Surg Oncol. 2014 Jul;21(7):2218-28.
38. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003 Nov;120(5):725-31.
39. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol. 2000 Sep;167(1-2):139-50.
40. Park S, Koo J S, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park B-W, Lee KS. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011;22(8):1755-1762.
41. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug;22(8):1736-47.
42. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010 Dec;124(3):607-17.
43. Hodgson MC, Vanostran G, Alghamdi S, Poppiti RJ, Agoulnik AI, Agoulnik IU. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. PLoS One. 2013 Apr;8(4):e60455.
44. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 2008 Jun;10(6):542-8.
45. Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E, de Cremoux P, de Bazelaire C, Albiter M, Giacchetti S, Cuvier C, Janin A, Espié M, de Thé H, Bertheau P. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res. 2013 May;15(3):R37.
46. Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch. 2006 Jul;449(1):24-30.
47. Søiland H, Kørner H, Skaland I, Janssen EA, Gudlaugsson E, Varhaug JE, Baak JP, Søreide JA. Prognostic relevance of androgen receptor detection in operable breast cancer. J Surg Oncol. 2008 Dec;98(7):551-8.
48. Mrklic´ I, Pogorelic´ Z, Capkun V, Tomic´ S. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochemica. 2013 May;114(4):344-8.
49. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011 Jun;30(15):3019-27.
50. Sutton LM, Cao D, Sarode V, Molberg KH, Torgbe K, Haley B, Peng Y. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol. 2012 Oct;138(4):511-6.
51. Tang D, Xu S, Zhang Q, Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol. 2012 Jun;29(2):526-33.
52. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP, Hawse JR, Henry TJ, Barrett MT,Cunliffe HE, Pockaj BA. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol. 2014 Feb;21(2):361-7.
53. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007 Jan;109(1):25-32.
54. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012 Jun;29(2):406-10.
55. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010 Mar;21(3):488-92.
56. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013 Oct;19(19):5505-12.
57. Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015 Mar;14(3):769-78.
58. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan;16(1):R7.

Поиск по сайту